People with systemic lupus erythematosus (SLE) who have been in remission for at least a year and take low-dose prednisone as maintenance therapy have less risk of a disease relapse than those who stop taking it, a recent study suggests. The study, “Withdrawal of low-dose prednisone in…
PRV-3279, a potential therapy for people with systemic lupus erythematosus (SLE), durably blocks B-cells to prevent them from producing damaging antibodies, but does not deplete these key immune defense system cells, results from the first part of a Phase 1b/2 trial show. The Phase 1b portion of the PREVAIL study (…
Researchers investigated health care use by people with systemic lupus erythematosus (SLE) and found that patients were more apt to seek clinical care during the first few years after diagnosis, but became less inclined over time. SLE patients also tend to turn increasingly more to general physician care, over encounters with specialists such as rheumatologists. The research…
Findings from a large “Treat-to-Target” (T2T) study of systemic lupus erythematosus (SLE), focusing on patient and disease characteristics, and factors influencing a low disease activity state — associated with better long-term outcomes — were presented at the recent Australian Rheumatology Association Annual Scientific Meeting in Darwin. Treat-to-Target (T2T), an approach used for the design…
Researchers developed a new monoclonal antibody against specific cells and molecules involved in systemic lupus erythematosus (SLE) that has shown potential both in vitro and in vivo studies. The findings have led the scientists to believe the antibody is ready for clinical testing in people as a potential new therapeutic agent. The study, by researchers at…
Mallinckrodt Pharmaceuticals announced the results of three retrospective analyses that studied H.P. Acthar Gel in three distinct patient populations — relapsing multiple sclerosis (MS), systemic lupus erythematosus (SLE), and sarcoidosis. Results from each study, which focused on the product from a health economics perspective, were presented in poster sessions at…
Researchers have identified a key molecular pathway that drives the maturation of antibody-producing B-cells, capable of weeding out harmful pathogens. The discovery may allow scientists to manipulate antibody responses to create new treatments for autoimmune diseases such as lupus. The study, “A TRAF-like motif of the inducible costimulator ICOS controls development of germinal center TFHcells via…
Salk Institute researchers have shown how FDA-approved rapamycin might have an additional therapeutic effect due to its ability to target the neural damage associated with Leigh syndrome and, potentially, other neurodegenerative diseases. The drug has also been shown to alter the immune system, extend patients’ lifespan, and treat disorders such as lupus…
Corbus Pharmaceuticals announced the addition of a protocol amendment to one of the company’s existing Investigational New Drug (IND) Applications with the FDA for a Phase 2 clinical trial of Resunab for the treatment of systemic lupus erythematosus (SLE), an important step to initiate a multicenter placebo-controlled SLE trial. The clinical study,…
In a landmark study, principal researcher Virginia Pascual at the Baylor Institute for Immunology Research, and colleagues, investigated the molecular diversity of lupus and found that a personalized immuno-monitoring approach allows for classification of patients into specific disease groups. Researchers believe these results may explain why lupus clinical trials have a low success rate…